Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Newswire

Published November 12, 2026 · Updated November 13, 2026

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences' Low-Dose Psilocybin ...

Read the full story at Newswire

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences' Low-Dose Psilocybin Research on PTSD and Concussion. Press Release • Nov 12, 2026 08:00.

Surfaced by this Google Alert

  • Psychedelic press release